Lansforsakringar Fondforvaltning Ab (Publ) Sarepta Therapeutics, Inc. Transaction History
Lansforsakringar Fondforvaltning Ab (Publ)
- $17 Billion
- Q2 2025
A detailed history of Lansforsakringar Fondforvaltning Ab (Publ) transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Lansforsakringar Fondforvaltning Ab (Publ) holds 12,740 shares of SRPT stock, worth $224,606. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,740
Previous 12,740
-0.0%
Holding current value
$224,606
Previous $813,000
73.31%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding SRPT
# of Institutions
444Shares Held
82.6MCall Options Held
5.61MPut Options Held
4.17M-
Vanguard Group Inc Valley Forge, PA10.8MShares$191 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$182 Million0.04% of portfolio
-
State Street Corp Boston, MA4.7MShares$82.8 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY4.48MShares$79 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA2.53MShares$44.6 Million0.01% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $1.54B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...